Triple combo works in second-line treatment of multiple myeloma
A treatment combination comprising pomalidomide, bortezomib, and dexamethasone appears to be effective in multiple myeloma patients for whom lenalidomide is no longer an option, including those refractory to lenalidomide, according to the results of the phase III OPTIMISMM trial.